-
The renewal of the Hunan antibiotics standard is good for the selected enterprises in the national procurement!
Time of Update: 2021-08-28
Antimicrobial drugs whose generic name or dosage form is not in the above procurement catalogue shall be included in the monitoring catalogue in accordance with the relevant regulations of Hunan Province on drug listing .
-
The national key monitoring catalogue is adjusted every two years, and Chinese medicine companies look to the non-medical insurance market
Time of Update: 2021-08-28
In the new version of the National Medical Insurance Catalogue published in August 2019, all key monitored drugs are transferred, including some varieties with relatively large annual sales, which may have an impact on the production and operation of individual enterprises .
-
The Medical Insurance Bureau and the Ministry of Finance jointly issued opinions on establishing a medical insurance benefit list system
Time of Update: 2021-08-28
August 10, the National Medical Insurance Bureau and Ministry of Finance jointly issued the "Opinions on the Establishment of Medicare benefits list system" . Reads as follows: National Insuranc
-
Guangdong Union pilots new rules?
Time of Update: 2021-08-28
For example, Shanghai in the "4 + 7" purchase agreement expires, the merger results in order to select Jicai, renewal Union rules areas: (a) "4 + 7" pilot areas were selected drugs and alliances, selected companies agreed to the city If the selected price is adjusted to the selected price for centralized drug procurement in the enterprise alliance area, the procurement cycle will be extended by 1 year .
-
The first health care product attracts 1.3 billion yuan in half a year, over 1 billion single product dominates the screen
Time of Update: 2021-08-28
Figure 1: The performance of BY-HEALTH in the past three years (unit: 100 million yuan) Source: The company's semi-annual report, BY-HEALTH, out of the haze of the epidemic, achieved the best record in both revenue and net profit in the first half of this year, with a year-on-year increase Respectively reached 34.
-
The state will gradually establish and improve the medical insurance benefit list system
Time of Update: 2021-08-28
The list of medical security benefits includes the basic system, basic policies, items and standards paid by the medical insurance fund, and the scope of non-payment .
-
Dongyang Pharmaceutical Class 1 new drug is coming!
Time of Update: 2021-08-28
According to data from Meinenet, in 2020, the sales of terminal anti-gout preparations in Chinese public medical institutions and physical pharmacies in cities in China will exceed 3 billion yuan .
-
100 billion market capitalization pharmaceutical stocks plummeted!
Time of Update: 2021-08-28
At present, there are 18 pharmaceutical stocks with a market value of 100 billion in the A-share market including Mindray Medical, WuXi AppTec, Hengrui Pharmaceuticals, Pien Tze Huang, etc.
-
Each box of Pfizer's star innovative drugs drops 40,000!
Time of Update: 2021-08-28
In addition to Pfizer, in the first half of this year, Eli Lilly, Sanofi, Xi'an Janssen and other multinational pharmaceutical companies have successively adjusted the prices of their star innovative drugs in various places .
-
Chia Tai Tianqing surpasses Hengrui's 5 major product sales soaring by more than 50% for the first time
Time of Update: 2021-08-28
According to data from Meinenet, in recent years, the size of protein kinase inhibitors in the terminal market of public medical institutions in China has maintained a double-digit growth, exceeding 26 billion yuan in 2020, a year-on-year increase of 29.
-
Does the 3 exclusive "absolute leaders" of TOP10 varieties of children's medicines exist?
Time of Update: 2021-08-28
com, among the 1,270 currently announced drugs included in the priority review and approval list, 108 are children’s drugs (based on product + manufacturer), 104 are chemical drugs, and 4 are proprietary Chinese medicines; from the therapeutic field Look, nervous system drugs, systemic anti-infective drugs, anti-tumor and immunomodulators are ranked in the top three .
-
The trillion market is under pressure!
Time of Update: 2021-08-28
Affected by policies such as mass procurement, national medical insurance negotiations, and rational use of drugs, superimposed on the effects of the new crown epidemic, the size of the terminal market of China's public medical institutions will decline for the first time in 2020, and the drug market structure will also change .
-
The "Second National Team" of public hospitals is here!
Time of Update: 2021-08-27
On June 17, 2021, the General Office of the State Council issued the "Notice on Issuing the Key Tasks for Deepening the Reform of the Medical and Health System in 2021" ", which mentioned “optimizing support for the development of medical institutions run by state-owned enterprises, and formulating relevant policy documents before the end of October 2021” .
-
The production of Rehmannia glutinosa has been reduced continuously, and the floods may detonate the market
Time of Update: 2021-08-27
6. Anticipation of the market outlook Since 2016, the price of rehmannia glutinosa has been fluctuating around 10 yuan, and the long-term continuous low-price operation has caused serious frustration of farmers' enthusiasm for planting .
-
Guizhou's measures to promote the high-quality development of the pharmaceutical industry
Time of Update: 2021-08-27
Medical Network, August 18 News On August 13, Guizhou Provincial Food and Drug Administration issued a notice on "Several Measures to Promote the High-Quality Development of the Pharmaceutical Indust
-
Insulin leader's first oral hypoglycemic drug will be approved to target 1.4 billion varieties
Time of Update: 2021-08-27
Medical Network News, August 17 Recently, Tonghua Dongbao Pharmaceutical's 4 generic listing applications for Sitagliptin phosphate tablets have entered the "under review" status, which is expected to usher in good news .
-
The market rebounded rapidly. People's welfare rose by 80%!
Time of Update: 2021-08-27
Yichang Renfu Pharmaceutical's Bupropion Hydrochloride Sustained-Release Tablets (Ⅱ) was approved for the first imitation, Nanjing Zhengda Tianqing's methanesulfonate The application for the imitation of safinamide tablets and doxylamine succinate tablets of Jiangxi Xinganjiang Pharmaceutical has also entered the "under review" status recently, and the three first generic drugs are expected to boost the neurochemical drug market .
-
The best-selling plaster Hunan pharmaceutical company will be in the bag
Time of Update: 2021-08-27
Pharmaceutical Network News on August 16 A few days ago, Hunan Jiudian Pharmaceutical entered the administrative examination and approval stage with the imitation of 4 types of flurbiprofen gel plaster, which is expected to become the first domestic plaster to be reviewed .
-
Shandong pharmaceutical companies won 7 blockbuster varieties!
Time of Update: 2021-08-27
0 Chinese drug review database consistency evaluation application, New Era Pharmaceuticals also has 8 varieties in the "under review and approval" status, of which There are 7 injections .
-
Soaring 129% of the anti-tumor injection Hausen will win
Time of Update: 2021-08-27
Medical Network News on August 17 Recently, Hausen’s application for the imitation of azacitidine for injection in the category 4 listing has entered the "under review" status, and if it is successfully approved, it will become the fourth domestic company .
